28th Apr 2014 09:33
LONDON (Alliance News) - GW Pharmaceuticals PLC said Monday that its compound Sativex had been granted a Fast Track designation by the US Food and Drug Administration, for the treatment of pain in patients with advanced cancer.
The treatment is for patients whose pain is not adequately handled by therapy with opioids, such as morphine. It is currently in Phase 3 clinical trials.
The designation is intended to speed up the drug's development, review and potential approval.
"We are fully committed to delivering the first FDA-approved cannabinoid medicine for these patients who currently have nowhere else to turn," Chief Executive Justin Gover said in a statement.
Shares in GW Pharmaceuticals were trading up 9.0% at 343.49 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L